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Background: ZASC1 is a zinc finger-containing transcription factor that was previously shown to bind to specific
DNA binding sites in the Moloney murine leukemia virus (Mo-MuLV) promoter and is required for efficient viral
mRNA transcription (J. Virol. 84:7473-7483, 2010).
Methods: To determine whether this cellular factor influences Mo-MuLV replication and viral disease pathogenesis
in vivo, we generated a ZASC1 knockout mouse model and completed both early infection and long term disease
pathogenesis studies.
Results: Mice lacking ZASC1 were born at the expected Mendelian ratio and showed no obvious physical or
behavioral defects. Analysis of bone marrow samples revealed a specific increase in a common myeloid progenitor
cell population in ZASC1-deficient mice, a result that is of considerable interest because osteoclasts derived from
the myeloid lineage are among the first bone marrow cells infected by Mo-MuLV (J. Virol. 73: 1617-1623, 1999).
Indeed, Mo-MuLV infection of neonatal mice revealed that ZASC1 is required for efficient early virus replication in
the bone marrow, but not in the thymus or spleen. However, the absence of ZASC1 did not influence the timing of
subsequent tumor progression or the types of tumors resulting from virus infection.
Conclusions: These studies have revealed that ZASC1 is important for myeloid cell differentiation in the bone
marrow compartment and that this cellular factor is required for efficient Mo-MuLV replication in this tissue at an
early time point post-infection.
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Transcription of retroviral genomes involves numerous
cellular transcription factors that bind to the unique
3′ (U3) enhancer element located in the viral promoter
[1-4]. These transcription factors can dictate viral cell-
type tropism as well as the types of viral diseases that
are elicited [5-7]. For example, in the case of Moloney
murine leukemia virus (Mo-MuLV) mutations in the
core binding site primarily induce erythroleukemia in-
stead of thymic lymphoma [7].* Correspondence: jyoung@salk.edu
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reproduction in any medium, provided the orPreviously, our groups employed a forward genetic
screen that identified ZASC1 (Zinc Finger Amplified in
Esophageal Squamous Carcinoma 1 or ZNF639) as a
cellular transcription factor that binds three specific
DNA sequences located within the U3 region of the
Mo-MuLV genome [8]. ZASC1 is a 9-C2H2 zinc finger
protein [9] that binds and translocates alpha-N-catenin
to the nucleus [10] and also interacts with the CREB
binding protein (CBP) [11]. We also showed that ZASC1
promotes viral gene expression in established cultured
cell lines [8]. More recently we have found that ZASC1
is also required for efficient HIV-1 gene expression by a
mechanism that is associated with recruitment of a viral
Tat/cellular pTEFb complex to the viral core promoter
(Bruce et al. in preparation).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion and disease pathogenesis in vivo, we have now gen-
erated a ZASC1−/− mouse strain. We report here that
ZASC1-knockout mice exhibit an early viral replication
defect in bone marrow that is associated with a specific
defect in myeloid cell differentiation.
Results
Generation and characterization of ZASC1−/− mice
To address the potential role of ZASC1 in wild type (WT)
Mo-MuLV replication and disease pathogenesis in vivo,
we generated a ZASC1 conditional knockout mouse
(Figure 1A). ZASC1 contains 7 exons and the open read-
ing frame is located in exons 4–7. LoxP sites were intro-
duced into the DNA sequences flanking ZASC1 exons
4–7 so that the complete ZASC1 open reading frame was
deleted following Cre-mediated recombination. The first
loxP site was inserted into the intron between exons 3 and
4 using a puromycin (puro) selection cassette. A second
loxP site was inserted downstream of exon 7 and the
polyadenylation signal as part of a neomycin (neo) cassette
to select for insertion of this site. The neo and puro cas-
settes, flanked by F3 and Frt sites respectively, were
excised in the presence of Flp recombinase.
The targeting vector was inserted into 129/J ES cells
and 294 G418-resistant colonies were selected. Embry-
onic stem (ES) cell clones were screened for homologous
recombination by southern blot analysis detecting a
5041 bp restriction fragment that was diagnostic of
homologous recombination (Figure 1B). Positive cell
clones were subsequently screened to identify those that
also contained the upstream arm of the targeting vector,
and the two clones with the best morphology were
chosen for injection into C57bl/6 blastocysts. Chimeric
males were bred for germline transmission of the ZASC1
allele and screened by coat color.
After germline transmission was achieved, mice were
crossed to ß-actin-Flp+ C57bl/6 in order to remove the
antibiotic resistance cassettes in the targeting construct
to generate ZASC1+/fl mice. Finally, ZASC1+/fl mice
were bred to a CMV-Cre C57bl/6 to generate ZASC1−/−
mice. Future generations of ZASC1+/− heterozygotes
were bred to generate ZASC1−/− offspring. Quantitative
PCR analysis of tail genomic DNA confirmed the
complete deletion of exons 4–7 in ZASC1 from the
ZASC1fl/fl animals expressing CMV-cre (Figure 1C). RT-
PCR analysis of whole blood samples demonstrated that
ZASC1 expression was also completely absent in
ZASC1−/− mice (Figure 1D). ZASC1−/− mice were born
at normal Mendelian ratios and had similar weights
and lifespans as compared to their WT littermates (data
not shown). Furthermore, deletion of ZASC1 did not
cause any obvious physical or behavioral defects (data
not shown).ZASC1−/− mice have normal levels of B and T
lymphocytes
Because ZASC1 is expressed ubiquitously and MLV pri-
marily infects hematopoietic cell types, we first analyzed
the major hematopoietic cell populations in lymphoid
organs by flow cytometry. These studies revealed no de-
ficiency in the proportion of T-cells or B-cells in the
spleen (Figure 2A and 2B) and thymus (Figure 2C and
2D) of ZASC1−/− mice as compared to WT mice. More-
over, T-cells derived from young ZASC1−/− mice showed
no functional defect when tested for activation in vitro
(Additional file 1: Figure S1). Therefore, we conclude
that ZASC1 deficiency does not significantly alter mouse
splenic or thymic B or T cell populations.
ZASC1-deficient mice exhibit an altered bone marrow
common myeloid progenitor cell population
Previously, myeloid cell populations in the bone marrow
were shown to be among the first cells infected by Mo-
MuLV [12]. Therefore, flow cytometric analysis was used
to examine the progenitor cell populations in the bone
marrow. These cells were identified by a lack of lineage
specific markers (lin-) and expression of sca-1 and c-kit
on their surface. The lin-sca+kit+ (LSK) population
contained the earliest bone marrow progenitors: hema-
topoietic stem cells (HSCs) were identified by gating on
the CD105+ and CD150+ population whereas multi-
potent progenitors (MPPs) were identified by gating on
the CD105+ CD150- cell subset, as described in [13].
The LK compartment (lin-sca-kit+) is known to contain
myeloid and erythroid progenitors (Additional file 2:
Figure S2) [14]. We found that HSC and MPP populations
were comparable between ZASC1−/− and ZASC1+/+ mice,
but there was a statistically significant 1.5-fold increase
(p-value = 0.012) in the heterogenous lin-ska-kit+ (LK)
compartment in all ZASC1-deficient animals tested
(Figure 3A and 3B). This compartment contains com-
mon myeloid progenitor cells and downstream myeloid
precursors with no long-term repopulation potential
[14]. We conclude that ZASC1 deficiency specifically
leads to altered common myeloid progenitor cell differ-
entiation in the bone marrow.
Early defect in Mo-MuLV replication in the bone marrow
of ZASC1−/− mice
To address the role of ZASC1 in early retrovirus infec-
tion in vivo, a preliminary time course of infection was
performed in mixed background 129 J and C57bl/6 mice
with ZASC1+/+, ZASC1+/− and ZASC1−/− genotypes.
Neonatal mice were inoculated p2-p3 by i.p. injection
and viral titers were measured in the spleen, thymus,
and bone marrow using an established focal immuno-
fluorescence assay [15] at various time points post infec-
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Figure 1 Generating the ZASC1−/− mouse model. A.) Schematic representation of the ZASC1 genomic locus (top) and ZASC1 locus after
inserting loxp sites via cassettes containing puromycin and neomycin resistance genes. White boxes represent exons. Black line represents
intronic or other sequence. Black arrow indicates translational start site. eGFP with a splice acceptor sequence was inserted downstream of the
Neomycin targeting in an effort to express eGFP from recombined ZASC1 gene. B.) Southern blot of Sph1-digested DNA showing homologous
recombination at the ZASC1 locus in genomic DNA isolated from 129 J ES cells; the 8,213 bp band represents the ZASC1 genomic locus and the
5,041 bp band represents the floxed ZASC1 locus. C.) ZASC1 gene copy number measured by qPCR, normalized to GAPDH gene copy number, in
animals with different ZASC1 genotypes. D.) ZASC1 RNA expression in whole blood cells from each ZASC1 genotype measured by RTPCR. Lower
band in ZASC1−/− lane represents primer-dimer.
Seidel et al. Virology Journal 2013, 10:130 Page 3 of 9
http://www.virologyj.com/content/10/1/130virus titers in the bone marrow of ZASC1−/− mice were
significantly lower than those found in ZASC1+/− mice
10 days post infection (p-value = 0.03).
To investigate this early defect in Mo-MuLV repli-
cation in the bone marrow in more detail, the study
sample size was increased and bone marrow samples
were harvested at 10 days post-infection. This ana-
lysis revealed a highly statistically significant 5.1-fold
(p-value = 0.025) and 4.2-fold (p-value = 0.047)
decrease in MLV replication in ZASC1−/− mice as
compared to ZASC1+/+ or ZASC1+/− mice respect-
ively (Figure 4A).To determine if this replication defect was specific for
one or more cell types in the bone marrow, we mea-
sured the virus titers in T-cell, B-cell, and in non-B/T
cells in samples taken from several animals that were
pooled by genotype. Mature T-cells and B-cells were
immunopurified using CD90.2- or B220-coated magnetic
beads respectively and flow cytometry was used to con-
firm cell population purity and the efficiency of T/B cell
depletion (data not shown). Consistent with our previ-
ous results, the complete bone marrow samples derived
from ZASC1−/− animals supported 6.5-fold less Mo-
MuLV replication as compared to ZASC1+/+ (Figure 4B).
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Figure 2 ZASC1 is not required for normal differentiation of splenocytes or thymocytes. Spleen and thymus from ZASC1+/+ and ZASC1−/−
animals were harvested and stained using α-CD3, α-B220, α-CD11b, α-CD4, and α-CD8 fluorophore-conjugated antibodies and analyzed by flow
cytometry. A.) Example of gating for mature cell populations after FSC/SSC analysis to gate on live cells. Top panel shows T-cell subsets (CD4+
and CD8+). Middle panel shows B-cells (B220) and T-cells (CD3). Bottom panel shows monocytes/macrophages (CD11b). B.) Graphical
representation of the FACS plots shown in panel A. C.) Example of gating for CD4+, CD8+, and double positive thymocytes. D.) Graphical
representation of thymocyte populations shown in panel C. N=3 mice per group with littermate controls. Error bars = SD. No statistical
significance was observed between the different animal genotypes by two-tailed T-test.
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when we examined the bone marrow-derived T-cell,
B-cell, and non-B/T cell populations (Figure 4B). There-
fore, the difference in virus infection seen between
ZASC1−/− versus ZASC1+/+ animals at an early time
point appears to apply generally to all cell types in the
bone marrow.
We also asked whether ZASC1 plays a role in
long-term Mo-MuLV pathogenesis by infecting neo-
natal mice with Mo-MuLV at the p2-p3 stage and
monitoring for up to 1 year for tumorigenesis. Mori-
bund animals were analyzed for tumor type, timing,
and severity. Despite the early virus replication defect
in the bone marrow, we found that ZASC1 had no
significant impact on disease outcome (Figure 4C
and 4D).Discussion
In this study, we developed a gene knockout model to
investigate the roles of ZASC1 in murine development
and retroviral pathogenesis. This cellular gene was previ-
ously shown to be important for efficient Mo-MuLV
infection in established cultured cell lines [8]. ZASC1-
deficient mice developed normally, had no fertility
defects, and exhibited normal T and B lymphocyte
numbers as well as normal levels of bone marrow
hematopoietic stem cells and multipotential progenitor
cells. However, ZASC1-deficiency was associated with a
significant increase in a myeloid progenitor cell popula-
tion (heterogenous lin-ska-kit+ or LK cells). The LK cell
compartment includes the common myeloid progenitor
(CMP), which ultimately gives rise to megakaryocytes,
erythrocytes, monocytes, granulocytes, and osteoclasts.
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LK LSK MPP HSC
Figure 3 ZASC1−/− mice have increased LK cell compartments in the bone marrow. A.) FACS plots gating hematopoietic progenitor
populations in the bone marrow. Antibodies used: α-c-kit, α-sca-1, α-CD105, α-CD150, and lineage markers (α-CD11b, α-Gr-1, α-Ter119, α-CD3,
α-Ly6C, α-CD19, α-CD11c). LK (Lin- Sca-1- C-kit+), LSK (Lin- Sca-1+ C-kit+), MPP (multipotent progenitor). and HSC (hematopoietic stem cell)
populations within the bone marrow were gated as labeled in the top left box. B.) Graphical representation of the LK, LSK and HSC populations
from multiple litters. N=3 mice per group. Mean average values. Error bars indicate SD. Two-tailed T-test was used to measure statistically
significant differences between ZASC1+/+ and ZASC1−/− populations. Significant p-value is indicated.
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in the bone marrow at an early time point post-infection.
This defect was seen with both lymphocyte and non-
lymphocyte populations. Despite this early block to bone
marrow infection, long-term Mo-MuLV-induced disease
was unaffected by this cellular factor.
Previous studies had shown that early infection of the
bone marrow correlates with leukemogenicity of Mo-
MuLV [16]. Furthermore, cells of the myeloid lineage
make up the majority of cell types infected during early
stage Mo-MuLV infection after i.p. inoculation [12]. Spe-
cifically, osteoclasts and osteoclast precursors are among
the first cells infected and these cell types are derived
from the myeloid lineage [17]. Consequently, we envi-
sion at least two distinct models to explain the effect of
ZASC1-deficiency on early Mo-MuLV replication in thebone marrow. The first model predicts that the defect
seen with ZASC1−/− bone marrow myeloid cell differen-
tiation is responsible for the reduced level of initial in-
fection. Reduced infection of these cells could then
translate into a lower level of initial virus spread to other
cell types in the bone marrow, including lymphocytes.
These initial effects would presumably be subsequently
masked once the virus has been amplified in the other
bone marrow cell populations, explaining why we ob-
served no differences in virus titer in this compartment
at later time points or in long-term disease pathogenesis.
An alternative model is that ZASC1-deficiency leads
to a more general block to virus replication (presumably
at the level of viral gene expression) in all of the target
cells contained in the bone marrow. However, for this




























































































Figure 4 Mo-MuLV infection is delayed in ZASC1−/− mice at an early time point. A.) The offspring of ZASC1+/− breeding pairs were
inoculated i.p. with Mo-MuLV at p2-p3. Bone marrow from infected animals was harvested 10 days post infection along with tails to determine
ZASC1 genotype. Virus infection was measured by focal immunofluorescence assay to determine infectious centers per 106 cells. Each point
represents a single animal: ZASC1+/+ (circles), ZASC1+/− (squares), and ZASC1−/− (triangles). Mean average values indicated by horizontal bar.
Statistically significance measured by two-tailed T-test. p-values indicated on the graph. B.) Infections were completed as in panel A, but bone
marrow was pooled by genotype before magnetic cell sorting was used to purify T-cells and B-cells from the bone marrow. “Complete” is
unsorted bone marrow. “T-cells” were isolated from bone marrow using α-CD90.2 conjugated Dynabeads. “B-cells” were isolated from bone
marrow using α-B220 conjugated Dynabeads. Focal immunofluorescence assay was used to quantify infected cells in each population. Graph is
mean average levels of infection in WT cells. N=3 litters of mice pooled by genotype. Error bars show SD. Statistical significance measured using
one-way ANOVA. C.) Kaplan-Meier plot comparing survival of Mo-MuLV-infected animals of ZASC1+/+ (thick black), ZASC1+/− (thin black) and
ZASC1−/− (thick gray) genotypes. Litters of mice from ZASC1+/− breeding pairs were infected p2-p3 and were allowed to develop disease.
Animals that had not exhibited overt signs of disease were terminated 1 year post-infection. ZASC1+/+ (N=15), ZASC1+/− (N=31), ZASC1−/− (N=15).
D.) Stacked graph of tumor types by ZASC1 genotype.
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not associated with low virus titers in samples taken
early post-infection from either splenic or thymic T- or
B-cell populations. Future studies will be aimed at dis-
criminating between these two different models and ex-
ploring the putative role of ZASC1 in myeloid cell
differentiation.
Conclusions
We have generated a ZASC1 knockout mouse and dem-
onstrated that this mouse model has no obvious devel-
opmental or behavioral defects. When challenged with
Mo-MuLV infection, ZASC1 deficient animals exhibited
an early defect in Mo-MuLV replication in the bone
marrow compartment. Further analysis of this compart-
ment revealed an increase in the LK cell population, a
group of progenitor cells that give rise to myeloid celltypes including osteoclasts. Since osteoclasts in the bone
marrow are among the first cell types infected by
Mo-MuLV, these data suggest that ZASC1 might influ-
ence the number of these target cells available for
establishing Mo-MuLV infection. Alternatively, ZASC1
might directly influence Mo-MuLV transcription in the
bone marrow niche. Further studies will be needed to
distinguish between these two possible models.
Methods
Generation of the ZASC1 knockout mice
A ZASC1 targeting vector was cloned using a
recombineering approach, described in [18]. Briefly, loxP
sites were introduced in the intron between ZASC1
exons 3 and 4 and downstream of exon 7 with puro-
mycin and neomycin resistance cassettes. The integrity
of the ZASC1 targeting vector was confirmed by PCR
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as well as by restriction enzyme digestion. 129/J5 embry-
onic stem (ES) cells were electroporated (BioRad
GenePulser) with the ZASC1 targeting vector and se-
lected for integration in culture medium containing
200 μg/ml G418. G418 positive ES cell clones were ana-
lyzed for homologous recombination by Southern blot
analysis at each homologous arm.
The Salk Institute Transgenic Mouse Core Facility
performed blastocyst injections and highly chimeric
males (by coat color) were bred with C57bl/6 females.
Progeny with germline transmission of the targeted
ZASC1 locus were bred with a C57bl/6 transgenic
mouse expressing FLP recombinase from the human
Beta-actin promoter (Jackson Laboratory Stock Number
005703). Mice with FLP recombination were then bred
with CMV-Cre mice (Jackson Laboratory Stock Number
006054).
Genotyping
Tails collected from 14-day old pups were incubated
overnight in tail lysis buffer (100 mM Tris pH 8, 5 mM
EDTA, 2% SDS and 200 mM NaCl + Proteinase K) at
55°C for in house genotyping. DNA was purified by
ethanol precipitation and dried pellets were resuspended
in 500 μl TE. 1 μl diluted tail DNA samples were added
to a 10 μl qPCR reaction mix that also included geno-
typing primers and FAST SYBR Green Master Mix
(Applied Biosystems). Germline transmission of the
ZASC1 knockout locus was detected with primer pair
5′-TCAGTGCATCAGCATACTCAAG-3′ and 5-CTG
GTGGTTCTTCATCGGC-3′ and then normalized to
GAPDH using primer pair 5′-ACCCAGAAGACT
GTGGATGG-3′ and 5′-CACATTGGGGGTAGGAA
CAC-3′. qPCR analysis was performed using the
Applied Biosystems ViiA 7 instrument. Genotyping for
cre-recombinase, flp-recombinase and the floxed ZASC1
allele was done through a professional genotyping ser-
vice (Transnetyx Inc.).
Flow cytometric analysis
Spleen and thymus samples were harvested from eutha-
nized 4-week old animals and ground into a single cell
suspension through a 70 μM cell strainer and incubated
in ACK buffer (Life Technologies) to lyse red blood cells.
Bone marrow samples were harvested from euthanized
10-day old animals by crushing bones and straining
through a 70 μM filter. Cells were resuspended in stain-
ing buffer (3% BSA in PBS) on ice and incubated with
antibodies for 30 minutes before washing away unbound
antibodies. For spleen analysis, fluorescently-labeled
α-CD3, α-B220, α-CD11b, α-CD4, and α-CD8 antibodies
were used (eBiosciences). For thymus analysis, fluores-
cently-labeled α-CD4 and α-CD8 antibodies were used(eBiosciences). For bone marrow, α-c-kit, α-sca-1, α-
CD105, α-CD150, and lineage markers (α-CD11b, α-Gr-1,
α-Ter119, α-CD3, α-Ly6C, α-CD19, α-CD11c) were used
(eBiosciences and Steve Hedrick Lab, UCSD). Samples
were analyzed using the FACSAria III (BD) instrument
and FlowJo software (Tree Star, Inc.).
Mo-MuLV production and titer determination
Virus was generated in extracellular supernatants from
NIH 3T3-43D cells (Fan Lab, UC Irvine), filtered
through a 0.45 micron filter, aliquotted and stored at
−80°C. Viral titers were determined by Focal Immuno-
fluorescence Assay (FIA) in the presence of polybrene as
described previously [15]. Virus-infected cells were iden-
tified by staining with 538 antibody-producing super-
natant (Fan lab, UC Irvine) [19], and an AlexaFluor 488
Goat-anti-Mouse secondary IgG (Life Technologies).
Plates were scanned and colonies counted using the Fuji
FLA-5100 scanner.
The viral genome plasmid pCMMP-luciferase was
used to generate the Mo-MuLV reporter viruses and
mZBS-Mo-MuLV reporter virus, as described previously
[8]. Virus-containing supernatants were harvested 48 hr
post-transfection and treated with DNase (40 U/ml)
before aliquotting and freezing at −80°C.
In vivo infections
Virus was harvested from extracellular supernatants
from productively infected NIH3T3-43D cells and used
to infect p2-p3 pups by intraperitonealinjection in a total
volume of 25 μl Mo-MuLV (8×105 IU/ml). For early
time points, animals were sacrificed and spleen, thymus,
and bone marrow were collected in order to quantify
virus infection by FIA as described above. Briefly, single
cell suspensions of each tissue were generated as de-
scribed before and 10-fold serial dilutions of these cells
were co-cultured with NIH3T3 cells until these cells
reached confluency. Similar experiments were conducted
with T-cells, B-cells, and T/B-depleted samples that were
purified from pooled 10-day mouse bone marrow sam-
ples using the Dynabeads FlowComp Pan-T or Pan-B
cell isolation kits (Life Technologies). The cells were
then stained using antibodies described in [19].
Tumor diagnosis and histopathological analysis
For tumor studies, 2–3 day old pups were infected as
described above and monitored until they developed
disease. Tumors were diagnosed as described previously
[15]. Mice were observed daily for signs of lethargy,
hunched posture, and scruffy fur associated with
Mo-MuLV-induced tumors. Moribund animals were
sacrificed and necropsy was performed. Spleen, thymus,
liver, and kidney tissues were weighed and pieces of
these organs along with lymph nodes were snap frozen
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(US Biological) or 10% formaldehyde.
Fixed tissues were processed by Pacific Pathology, Inc.
Fixed tissue samples were embedded in paraffin and
5 μm sections were cut and studied under light micros-
copy after hematoxylin-eosin (H&E) staining. Additional
slides were prepared for immunofluorescence analysis by
rehydrating slides, performing antigen retrieval using a
sodium citrate buffer, and staining with primary rabbit
antibodies to CD3 (Abcam) or CD79B (Santa Cruz Bio-
technology) and with a secondary anti-rabbit antibody
(Life Technologies).
Additional files
Additional file 1: Figure S1. ZASC1 is not required for T-cell activation
and proliferation. Mature CD4+ and CD8+ T-cells were isolated from
mouse spleen and lymph nodes of 3-week-old ZASC1+/+ and ZASC1−/−
animals using α-CD4 and α-CD8 conjugated magnetic beads. Purified
cells were labeled with CFSE (Carboxyfluorescein diacetate succinimidyl
ester) and incubated with IL-2 on α-CD3, α-CD28 coated plates for 4 days
to induce T-cell activation and proliferation. CFSE intensity decreases by
50% with each round of cell division leading to peaks representing
different levels of proliferation. Flow cytometry histogram shows T-cell
proliferation in a representative ZASC1+/+ (red) and ZASC1−/− (blue)
littermate control.
Additional file 2: Figure S2. Flowchart of Hematopoietic Development.
Hematopoietic stem cells (HSC) are the self-renewing cell type capable of
repopulating the entire hematopoietic lineage. Cell surface molecules
used to identify these cells are listed. Differentiation is a step-wise
process in which cells lose repopulation potential and become
functionally mature cells within the immune system. CMP, common
myeloid progenitor; CLP, common lymphoid progenitor; MEP,
megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage
progenitor.
Additional file 3: Figure S3. Virus titers (infectious centers/106 cells)
were measured from spleen, thymus, and bone marrow of Mo-MuLV
infected animals collected at 7, 10 and 13 days post infection. Each dot
represents one animal. ZASC1+/+ animals were not shown because the
sample sizes were too small to draw meaningful conclusions. ZASC1+/−
(squares) and ZASC1−/− (triangles). Mean average values indicated by
horizontal bar. A.) Spleen B.) Thymus C.) Bone Marrow.
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Mo-MuLV: Moloney murine leukemia virus; LK: Lin-Ska-Kit+; LSK: Lin-Ska+Kit+.
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